Kinaset Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Boston, Massachusetts, 02052, United Sta...Phone Number
(508) 858-5810Website
www.kinasettherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Kinaset Therapeutics
Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing novel, inhaled therapies for severe respiratory diseases. Its lead program, frevecitinib, is a differentiated inhaled pan-JAK inhibitor designed to deliver broad anti-inflammatory activity directly to the lungs while minimizing systemic exposure, with the potential to address asthma that remains inadequately controlled by standard inhaled maintenance therapies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kinaset Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Kinaset Therapeutics launches new products
Click to see if Kinaset Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Kinaset Therapeutics recently announced quarterly report
Check if Kinaset Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Kinaset Therapeutics is spiking on competitors!
Kinaset Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Kinaset Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Kinaset Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Kinaset Therapeutics
Find more new buyers
Company Profile Activity
Activity Insights
Kinaset Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kinaset Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kinaset Therapeutics.
Kinaset Therapeutics financials insights
Gather financial insights about Kinaset Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$40M
2026
Series B
$103M
Kinaset Therapeutics Tech Stack
A closer look at the technologies used by Kinaset Therapeutics
Most Recent Scoops
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
Funding
Funding
Event
Events
Event
Events
Kinaset Therapeutics News & Media
Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to ...
BOSTON, January 10, 2026--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing a novel and differentiated inhaled therapeutic candidate to treat serious respiratory diseases, today announced the closing of a $103 million Series B financing. New investors RA Capital Management and Forge Life Science Partners led the financing, with participation from new investors EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty DegreeKinaset Therapeutics Announces FDA Clearance of IND Application for frevecitinib (KN-002) in Asthma Treatment
BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced that the United States Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for frevecitinib (KN-002). This novel inhaled dry powder therapeutic is in development for patients with asthma that remains inadequately controlled by standard of care inhaled maintenance therapies. TheseKinaset Therapeutics to Share Outcomes from the Phase 1 Clinical Evaluation of Frevecitinib (KN-002), an Inhaled Pan JAK Inhibitor, in Patients with Moderate to Severe Asthma and COPD via Oral Presentations and Poster at ERS Congress
BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced two oral presentations and a late breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress being held September 7-11, 2024, in Vienna, Austria. The presentations demonstrate the potential of Kinaset’s lead clinical candidate, frevecitinib (KN-002), to treat all patients with moderate to severeKinaset Therapeutics Debuts Positive Outcomes Data from Phase 1b Study of KN-002 at the 2024 American Thoracic Society (ATS) International Conference
BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics debuts positive outcomes from its Phase 1b study of KN-002 at the 2024 American Thoracic Society (ATS) International Conference.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kinaset Therapeutics
Sign Up For FreeTo access detailed company insights
Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing novel, inhaled therapies for severe respiratory diseases. Its lead program, frevecitinib, is a differentiated inhaled pan-JAK inhibitor designed to deliver broad anti-inflammatory activity directly to the lungs while minimizing systemic exposure, with the potential to add... Read More
